◎ Sugi Atlas

Atlas / Drug / Venetoclax

Venetoclax

drug
On this page

Also known as ABT-199Abt199GDC-0199RG-7601RG7601VenclextaVenclyxtoUNII-N54AIC43PWC45H50CLN7O7SABT 199CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPYABBVIEVENETOCLAX (ABT-199)SID174006982VenetocalxVenetoclaxVenetoclaxÊVenetoclaxÂ

Summary

Venetoclax (CHEMBL3137309) is an approved small-molecule antineoplastic agent (ATC L01XX52) targeting BCL2, BCL2L1, and BCL2L2-PABPN1; indicated across 46 conditions including b-cell chronic lymphocytic leukemia and neoplasm; with CIViC clinical evidence for 28 variant-indication associations (e.g. BCL2 G101V in chronic lymphocytic leukemia).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XX52
  • Targets: 4 (BCL2, BCL2L1, BCL2L2-PABPN1…)
  • Indications: 46 conditions
  • Clinical trials: 637
  • Precision-oncology evidence (CIViC): 28 variant–indication associations
  • Chemistry: 868.4 Da · C45H50ClN7O7S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3137309
NameVenetoclax
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID49846579
ChEBICHEBI:133021
ATCL01XX52
Molecular formulaC45H50ClN7O7S
Molecular weight868.4
InChIKeyLQBVNQSMGBZMKD-UHFFFAOYSA-N

SMILES: CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C

IUPAC name: 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

ChEBI definition: A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.

Pharmacological roles (ChEBI): apoptosis inducer, antineoplastic agent, B-cell lymphoma 2 inhibitor.

Also known as: ABT-199, Abt199, GDC-0199, RG-7601, RG7601, Venclexta, Venclyxto, Venetoclax, UNII-N54AIC43PW, C45H50CLN7O7S, ABT 199, CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY

Patent coverage: 3,760 distinct patent families (9,389 SureChEMBL compound mentions), from 5 matched compound structure(s). One matched structure accounts for 7,860 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
BCL2BCL2 apoptosis regulatorAntagonist113.3%P10415
BCL2L1Bcl-2-like 1Antagonist7.3286.5%Q07817
BCL2L2-PABPN1Bcl-2-like 2Antagonist6.61Q92843
MCL1MCL1 apoptosis regulator, BCL2 family memberAntagonist6.3563.7%Q07820

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Alpha-2C adrenergic receptor, Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter, Adenosine receptor A3, Histone-lysine N-methyltransferase NSD2, Histone-lysine N-methyltransferase NSD3, Cytochrome P450 2C9, Induced myeloid leukemia cell differentiation protein Mcl-1/BH3-interacting domain death agonist, Histone-lysine N-methyltransferase, H3 lysine-36 specific, Bcl2-associated agonist of cell death.

Bioactivity

ChEMBL activities: 59 potent at pChembl ≥ 5 of 63 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
BCL210.74Ki0.02nMCHEMBL_ACT_19145985
BCL210.44Ki0.04nMCHEMBL_ACT_17692386
BCL210.44Ki0.04nMCHEMBL_ACT_26599232
BCL29.62IC500.24nMCHEMBL_ACT_25860887
BCL29.47IC500.34nMCHEMBL_ACT_28777094
BCL29.41Kd0.39nMCHEMBL_ACT_29275472
BCL2L19Ki1nMCHEMBL_ACT_23168570
BCL29IC501nMCHEMBL_ACT_23237716
BCL28.92Ki1.2nMCHEMBL_ACT_24706400
BCL28.92IC501.2nMCHEMBL_ACT_28777184
BCL28.64IC502.3nMCHEMBL_ACT_28777619
BCL28.52EC503nMCHEMBL_ACT_18997203
BCL28.51Kd3.1nMCHEMBL_ACT_22775789
BCL28.13IC507.39nMCHEMBL_ACT_18472119
BCL28.13IC507.4nMCHEMBL_ACT_18752598
BCL27.77Ki17nMCHEMBL_ACT_24706411
BCL27.64IC5023nMCHEMBL_ACT_24662005
BCL27.6IC5025nMCHEMBL_ACT_25861165
BCL27.55IC5028nMCHEMBL_ACT_28777163
BCL27.54Kd29nMCHEMBL_ACT_25861233
BCL2L17.32Ki48nMCHEMBL_ACT_16557088
BCL2L17.32Ki48nMCHEMBL_ACT_16623350
BCL2L17.32Ki48nMCHEMBL_ACT_18243593
BCL2L17.32Ki48nMCHEMBL_ACT_18390906
BCL2L17.32Ki48nMCHEMBL_ACT_18568196
BCL2L17.32Ki48nMCHEMBL_ACT_24912417
BCL2L17.32Ki48nMCHEMBL_ACT_25006094
BCL2L17.32Ki48nMCHEMBL_ACT_25845824
BCL2L17.32Ki48nMCHEMBL_ACT_26314240
BCL2L17.28IC5052.7nMCHEMBL_ACT_18472127

Target pathways

Aggregated over 4 target gene(s): BCL2, BCL2L1, BCL2L2-PABPN1, MCL1.

Top Reactome pathways

47 total, by targets touching each:

PathwayTargetsGenes
Cytokine Signaling in Immune system3BCL2, BCL2L1, MCL1
Immune System3BCL2, BCL2L1, MCL1
Signaling by Interleukins3BCL2, BCL2L1, MCL1
Interleukin-4 and Interleukin-13 signaling3BCL2, BCL2L1, MCL1
Apoptosis2BCL2, BCL2L1
Intrinsic Pathway for Apoptosis2BCL2, BCL2L1
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members2BCL2, BCL2L1
Signal Transduction2BCL2, BCL2L1
Disease2BCL2L1, MCL1
Innate Immune System2BCL2, BCL2L1
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways2BCL2, BCL2L1
Cellular responses to stress2BCL2, BCL2L1
Programmed Cell Death2BCL2, BCL2L1
Diseases of signal transduction by growth factor receptors and second messengers2BCL2L1, MCL1
Inflammasomes2BCL2, BCL2L1
The NLRP1 inflammasome2BCL2, BCL2L1
Cellular responses to stimuli2BCL2, BCL2L1
Cellular response to chemical stress2BCL2, BCL2L1
KEAP1-NFE2L2 pathway2BCL2, BCL2L1
Nuclear events mediated by NFE2L22BCL2, BCL2L1
NFE2L2 regulating tumorigenic genes2BCL2, BCL2L1
Activation of BAD and translocation to mitochondria1BCL2
Activation of BH3-only proteins1BCL2
Developmental Biology1BCL2
Infectious disease1BCL2L1
RAF/MAP kinase cascade1BCL2L1
MAPK family signaling cascades1BCL2L1
MAPK1/MAPK3 signaling1BCL2L1
ESR-mediated signaling1BCL2
Signaling by Nuclear Receptors1BCL2

Dominant GO biological processes

GO termTargets
release of cytochrome c from mitochondria4
apoptotic process4
intrinsic apoptotic signaling pathway in response to DNA damage4
positive regulation of apoptotic process4
negative regulation of apoptotic process4
extrinsic apoptotic signaling pathway in absence of ligand4
regulation of apoptotic process4
negative regulation of autophagy3
response to cytokine3
negative regulation of anoikis3
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand3
regulation of intracellular signal transduction3
regulation of apoptotic signaling pathway3
transmembrane transport3
ovarian follicle development2

Indications & clinical

Indications

46 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
B-cell chronic lymphocytic leukemia4MONDO:0004948EFO:0000095
neoplasm4MONDO:0005070EFO:0000616
plasma cell myeloma3MONDO:0009693EFO:0001378
myelodysplastic syndrome3MONDO:0018881EFO:0000198
acute myeloid leukemia3MONDO:0018874EFO:0000222
mantle cell lymphoma3MONDO:0018876EFO:1001469
myeloid leukemia3MONDO:0004643MONDO:0004643
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
chronic myeloid leukemia2MONDO:0011996EFO:0000339
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
leukemia2MONDO:0005059EFO:0000565
lymphoma2MONDO:0005062EFO:0000574
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209
breast neoplasm2MONDO:0021100EFO:0003869
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
T-cell prolymphocytic leukemia2MONDO:0019468EFO:1000560
follicular lymphoma2MONDO:0018906MONDO:0018906
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
acute biphenotypic leukemia2MONDO:0020322MONDO:0019460
B-cell acute lymphoblastic leukemia2MONDO:0004947EFO:0000094
lymphoid leukemia2MONDO:0005402EFO:0004289
acute monocytic leukemia2MONDO:0007896EFO:0000221
acute promyelocytic leukemia2MONDO:0012883EFO:0000224
CD4+/CD56+ hematodermic neoplasm2MONDO:0019467EFO:0010580
marginal zone lymphoma2MONDO:0017604EFO:1000630
amyloidosis2MONDO:0019065EFO:1001875
Burkitt lymphoma1MONDO:0007243EFO:0000309
metastatic prostate carcinoma1MONDO:0004956EFO:0000196
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
prolymphocytic leukemia1MONDO:0001023MONDO:0001023
small cell lung carcinoma1MONDO:0008433EFO:0000702
kidney disorder1MONDO:0005240EFO:0003086
hereditary amyloidosis1MONDO:0018634MONDO:0019438
HIV infectious disease1MONDO:0005109EFO:0000180
chronic myelomonocytic leukemia1MONDO:0020311EFO:1001779
idiopathic pulmonary fibrosis0MONDO:0800504EFO:0000768

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 637.

Phase distribution

PhaseTrials
PHASE2238
PHASE1164
PHASE1/PHASE2116
PHASE355
Not specified38
PHASE2/PHASE316
PHASE45
EARLY_PHASE15

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04790045PHASE4NOT_YET_RECRUITINGLymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
NCT05144243PHASE4ACTIVE_NOT_RECRUITINGStudy to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT06571825PHASE4RECRUITINGRIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06763666PHASE4NOT_YET_RECRUITINGCLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
NCT07044687PHASE4RECRUITINGStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT02416388PHASE2/PHASE3RECRUITINGStudy to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
NCT03336333PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03462719PHASE3ACTIVE_NOT_RECRUITINGA Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03539744PHASE3ACTIVE_NOT_RECRUITINGA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03701282PHASE3ACTIVE_NOT_RECRUITINGAssessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03737981PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03768063PHASE3ACTIVE_NOT_RECRUITINGA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03836261PHASE3ACTIVE_NOT_RECRUITINGStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03844048PHASE3ACTIVE_NOT_RECRUITINGAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03868722PHASE2/PHASE3RECRUITINGAcalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
NCT03984448PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT04229979PHASE3ACTIVE_NOT_RECRUITINGGalinpepimut-S Versus Investigator’s Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04256317PHASE2/PHASE3RECRUITINGA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04269902PHASE3RECRUITINGTesting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04401748PHASE3ACTIVE_NOT_RECRUITINGStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04608318PHASE3ACTIVE_NOT_RECRUITINGIbrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04628026PHASE3RECRUITINGPhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04708054PHASE2/PHASE3RECRUITINGVenetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
NCT04965493PHASE3ACTIVE_NOT_RECRUITINGA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT05057494PHASE3ACTIVE_NOT_RECRUITINGA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05177731PHASE3ACTIVE_NOT_RECRUITINGVenetoclax + Decitabine vs. 7+3 Induction Chemotherapy in Young AML
NCT05183035PHASE3RECRUITINGVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05197192PHASE3RECRUITINGA Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05404906PHASE2/PHASE3RECRUITINGAZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
NCT05805098PHASE2/PHASE3RECRUITINGVenetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
NCT05939180PHASE2/PHASE3RECRUITINGVA vs DA for Newly Diagnosed Hig-risk AML
NCT05947851PHASE3RECRUITINGA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT06073821PHASE3ACTIVE_NOT_RECRUITINGStudy of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06361329PHASE3RECRUITINGComparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
NCT06428019PHASE3RECRUITINGA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06496308PHASE3RECRUITINGBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
NCT06544109PHASE2/PHASE3ENROLLING_BY_INVITATIONVenetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
NCT06846671PHASE3RECRUITINGA Study of BGB-16673 Compared to Investigator’s Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06852222PHASE3RECRUITINGA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06855810PHASE2/PHASE3RECRUITINGNewly-diagnosed Pediatric T-cell ALL Protocol

Clinical evidence (CIViC)

Variant × indication × effect (28 predictive associations from 36 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BCL2 G101VChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC BEID8174 +5
BCL2 D103YChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC BEID8312 +1
BCL2 A113GChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID8189
BCL2 F104LChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID8187
BCL2 F104SChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID8186
BCL2 G101AChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID8184
BCL2 L119VChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID8190
BCL2 R107_R110dupChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID8188
BCL2 R107_R110dupChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC BEID8309
BCL2 V156DChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC BEID8306
TP53 MutationChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC BEID6074
IDH1 MutationAcute Myeloid LeukemiaSensitivity/ResponseVenetoclaxCIViC CEID8856
IDH2 MutationAcute Myeloid LeukemiaSensitivity/ResponseVenetoclaxCIViC CEID8857
BCL2 D103EChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID8311 +1
BCL2 F104IFollicular LymphomaResistanceVenetoclaxCIViC CEID8375 +1
BCL2 A113GChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID8308
BCL2 D103VChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID8310
BCL2 G101VChronic Lymphocytic Leukemia/small Lymphocytic LymphomaResistanceVenetoclaxCIViC CEID8185
BCL2 R129LChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID8307
BTK C481RChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID10374
BTK C481YChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID10373
PLCG2 D1140EChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID10372
PLCG2 N571SChronic Lymphocytic LeukemiaResistanceVenetoclaxCIViC CEID10371
KDM6A LossAcute Myeloid LeukemiaSensitivity/ResponseVenetoclaxCIViC DEID11036
KDM6A LossAcute Myeloid LeukemiaSensitivity/ResponseVenetoclax + OlaparibCIViC DEID11037
BAX mutationAcute Myeloid LeukemiaResistanceVenetoclaxCIViC DEID12423
BCL2 OverexpressionLymphomaResistanceVenetoclax + DinaciclibCIViC DEID9313
BRAF V600EDiffuse Large B-cell LymphomaResistanceVenetoclaxCIViC DEID8952

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

19 molecules share ≥1 primary target. Top 19 by shared-target count:

MoleculeSourceStatusShared targets
EPIGALOCATECHIN GALLATEChEMBLPhase 3BCL2, BCL2L1, BCL2L2-PABPN1, MCL1
GOSSYPOLChEMBLPhase 3BCL2, BCL2L1, BCL2L2-PABPN1, MCL1
NAVITOCLAXChEMBLPhase 3BCL2, BCL2L1, BCL2L2-PABPN1, MCL1
OBATOCLAXChEMBLPhase 3BCL2, BCL2L1, BCL2L2-PABPN1, MCL1
METHYSERGIDEChEMBLPhase 4 (approved)BCL2L1, MCL1
SONROTOCLAXChEMBLPhase 3BCL2, BCL2L1
APOMORPHINEChEMBLPhase 4 (approved)MCL1
BITHIONOLChEMBLPhase 4 (approved)MCL1
COUMARINChEMBLPhase 4 (approved)MCL1
HEXACHLOROPHENEChEMBLPhase 4 (approved)MCL1
IXABEPILONEChEMBLPhase 4 (approved)BCL2
LIOTHYRONINEChEMBLPhase 4 (approved)MCL1
OMEPRAZOLEChEMBLPhase 4 (approved)MCL1
PROCHLORPERAZINEChEMBLPhase 4 (approved)MCL1
ASARETOCLAXChEMBLPhase 2BCL2L1
CHLORCYCLIZINEChEMBLPhase 2BCL2
FORMONONETINChEMBLPhase 2BCL2
HYMECROMONEChEMBLPhase 2MCL1
LACUTOCLAXChEMBLPhase 2BCL2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot